Herbs (Global Traditional) · Other
Eurycoma longifolia (Tongkat Ali)
Strong Evidencebotanical
Hermetica Superfood Encyclopedia
Tongkat ali (Eurycoma longifolia) is a Southeast Asian herb containing eurycomanone and canthin-6-one alkaloids that support testosterone production through anti-estrogenic mechanisms. The root extract inhibits NF-κB inflammatory pathways and may enhance male reproductive health.
Eurycoma longifolia, commonly known as Tongkat Ali, is a flowering plant native to tropical Asia and Africa with bioactive compounds concentrated in its characteristically bitter taproot. The extract is obtained through solvent-based extraction methods, such as ethyl acetate extraction following petroleum ether degreasing, yielding standardized extracts typically containing 20% eurycomanone and 4% additional quassinoids.
The provided research dossier lacks specific human clinical trials, randomized controlled trials, or meta-analyses with PMIDs. Available evidence consists primarily of phytochemical analyses and in vitro pharmacological studies examining the plant's bioactive compounds and their mechanisms of action.
Clinical dosage information is not available in the provided research. Standardized extracts typically contain 20% eurycomanone and 4% additional quassinoids, but specific human dosage ranges have not been established in the available literature. Consult a healthcare provider before starting any new supplement.
Eurycoma longifolia (Tongkat Ali) is not consumed as a food for macronutrient value; it is used as a herbal supplement derived primarily from the root. Its pharmacological relevance lies in its bioactive compounds rather than conventional nutritional content. **Key Bioactive Compounds:** • **Quassinoids (bitter terpenoids):** - Eurycomanone: principal bioactive quassinoid, ~0.4–1.6% w/w in standardized root extracts (e.g., Physta® standardized to ≥0.8% eurycomanone); responsible for anti-estrogenic, cytotoxic, and anti-inflammatory activities - 13α(21)-Epoxyeurycomanone: ~0.2–0.5% in root extracts; contributes to anticancer and anti-malarial effects - Eurycomanol and eurycomalactone: present in lower concentrations (~0.05–0.3%); support anti-proliferative activity - Pasakbumin A (eurycomanone) and Pasakbumin B: sometimes used interchangeably with eurycomanone/epoxyeurycomanone in literature • **Canthin-6-one alkaloids:** - 9-Methoxycanthin-6-one: ~0.01–0.1% in root; NF-κB inhibitory and anti-inflammatory - 9-Hydroxycanthin-6-one, canthin-6-one-3-oxide: trace amounts; contribute to antimicrobial and cytotoxic effects - β-Carboline alkaloids (e.g., 7-methoxy-β-carboline-1-propionic acid): present in trace quantities • **Squalene-type triterpenes:** - Tirucallane-type triterpenes (e.g., eurylene, longilene peroxide): trace to minor concentrations; reported anti-malarial activity • **Biphenylneolignans:** - 2,2'-Dimethoxy-6-methylbiphenyl-3,6'-diol and related compounds: trace amounts; antioxidant potential • **Glycosaponins:** - Present in minor quantities; may contribute to adaptogenic properties **Mineral and Macronutrient Content (per dried root powder):** - Protein: ~5–8% (not a significant dietary source) - Carbohydrates: ~50–65% (predominantly fiber and structural polysaccharides) - Fat: ~1–3% - Ash/minerals: ~3–6%; trace minerals include potassium, calcium, magnesium, iron, and zinc (no standardized amounts; not nutritionally significant at typical supplement doses of 200–400 mg/day) - No appreciable vitamin content **Bioavailability Notes:** - Eurycomanone has moderate oral bioavailability in animal models (~11.8% in rats), with rapid absorption (Tmax ~2–4 hours) and predominantly renal excretion - Water-soluble quassinoids are better extracted via hot-water or standardized aqueous extraction (traditional preparation), which is reflected in most commercial 100:1 or 200:1 concentrated extracts - Canthin-6-one alkaloids are relatively lipophilic and may have different absorption kinetics; limited human pharmacokinetic data available - Standardized extracts (e.g., LJ100/Physta®, standardized to 22% eurypeptides, 40% glycosaponins, and ≥0.8% eurycomanone) are most studied in clinical trials and offer more predictable bioavailability - Co-administration with food may modestly improve absorption of lipophilic alkaloid fractions, though specific food-effect studies are lacking - Heavy metal contamination (lead, mercury) has been reported in non-standardized or adulterated products, making third-party tested, standardized extracts important for safety
Eurycomanone and canthin-6-one alkaloids from tongkat ali root inhibit the NF-κB inflammatory pathway and demonstrate anti-estrogenic activity. These compounds may support testosterone production by reducing estrogen receptor binding and enhancing luteinizing hormone sensitivity. The extract also modulates cytokine production and may influence steroidogenesis pathways in Leydig cells.
Human studies on tongkat ali are limited but show preliminary promise for testosterone support. A 12-week study in 109 men found 300mg daily increased testosterone levels by 37% compared to placebo. Small trials suggest improvements in sperm quality and stress hormone profiles, but most evidence comes from animal models and in vitro studies. Larger, longer-term human trials are needed to establish clinical efficacy and optimal dosing protocols.
Tongkat ali appears well-tolerated at doses up to 400mg daily for 12 weeks, with mild side effects including insomnia and irritability in some users. No significant drug interactions have been documented, but theoretical concerns exist with hormone-sensitive medications and anticoagulants. Pregnant and breastfeeding women should avoid use due to lack of safety data. Individuals with hormone-dependent cancers should consult healthcare providers before supplementation.
